TipRanks
Supernus Pharmaceuticals (DE:S49)
FRANKFURT:S49
Germany Market
S49
Supernus Pharmaceuticals
RESEARCH TOOLSreports

Supernus Pharmaceuticals (S49) Income Statement

0 Followers

Supernus Pharmaceuticals Income Statement

Last quarter (Q2 2026), Supernus Pharmaceuticals's total revenue was $219.06M, an increase of 32.40% from the same quarter last year. In Q2, Supernus Pharmaceuticals's net income was $-58.37M. See Supernus Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Dec 24Dec 23Dec 22Dec 21
Total Revenue
$ 718.95M$ 661.82M$ 607.52M$ 667.24M$ 579.77M
Gross Profit
$ 644.39M$ 583.91M$ 523.74M$ 580.02M$ 504.71M
Operating Expenses
$ 681.25M$ 502.25M$ 529.01M$ 533.89M$ 418.69M
Depreciation and Amortization
$ 91.56M$ 80.41M$ 84.86M$ 85.54M$ 32.59M
EBITDA
$ 42.53M$ 178.28M$ 90.04M$ 153.36M$ 129.19M
Operating Income
$ -36.86M$ 81.67M$ -5.27M$ 46.12M$ 86.03M
Other Income/Expenses
$ -12.17M$ 16.20M$ 8.04M$ 14.62M$ -12.85M
Pretax Income
$ -49.03M$ 97.87M$ 2.77M$ 60.74M$ 73.17M
Net Income
$ -38.55M$ 73.86M$ 1.32M$ 60.71M$ 53.42M
Per Share Metrics
Basic EPS
$ -0.68$ 1.34$ 0.02$ 1.13$ 1.01
Diluted EPS
$ -0.68$ 1.32$ 0.02$ 1.04$ 0.98
Weighted Average Shares Outstanding
 56.45M 55.10M 54.54M 53.67M 53.10M
Weighted Average Shares Outstanding (Diluted)
 56.45M 55.96M 55.51M 61.68M 54.36M
Currency in USD

Supernus Pharmaceuticals Earnings and Revenue History